Roche has had a good week, sharing positive two-year data from Genentech’s study on Vabysmo for age-related macular degeneration and eight-year data in its trial for combination therapy for HER2-positive early breast cancer.
https://www.pharmalive.com/wp-content/uploads/2022/03/Roche-Plans-Ambitious-Phase-III-Alzheimers-Study-BioSpace-3-3-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-07-15 12:34:202022-07-15 12:34:57Roche wraps week with a bang, touting long-term breast cancer, AMD data
